REFLECTIONS OF A PHARMACIST, ACADEMIC AND RESEARCHER IN A PIVOTAL YEAR OF CHANGE FOR THE PHARMACY PROFESSION
Dr Kate Wang, Senior Lecturer in Pharmacy, RMIT University &
Adjunct Senior Lecturer, University of Western Australia
PEOPLE IN HEALTH CARE
Filmed in Melbourne, Victoria | December 2024
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
With Australia’s ageing population projected to reach 21-23% of those over 65 by 2060, the need for effective medication management is crucial. Older adults often face multiple chronic conditions and take multiple medications, making pharmacists essential as medication experts.
Pharmacists are the most accessible healthcare professionals in Australia, allowing for regular patient interactions. This consistent contact enables them to provide ongoing monitoring and health management, highlighting the importance of expanding their scope of practice. Dr. Wang emphasises the trialing of structured prescribing for conditions like uncomplicated urinary tract infections and oral contraceptives, where timely access is vital.
Attending the PSA24 conference hosted by the Pharmaceutical Society of Australia in Sydney, she noted the collaborative efforts among healthcare professionals to address changes in scope of practice. The process requires thorough review and piloting, with a commitment to patient centred care. As the field evolves, pharmacists must adapt to new treatments and emerging health challenges, continuously striving to make a positive impact on individuals and the broader community.
-
Clinical trial site in primary care setting open for novel therapies in psychiatry
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
-
HEALTH CARE BRIEF: Type 1 Diabetes (T1D)
Type 1 Diabetes – Incidence rates, management, lived experience & research
-
Investigating use of dietary supplements for osteoarthritis
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
